plutonium citrate profile

Plutonium citrate is a radioactive compound formed by the interaction of plutonium ions with citrate ions. While its specific synthesis methods are not widely published due to its radioactive nature and potential safety concerns, it is likely produced in a controlled environment with specialized equipment. Plutonium citrate exhibits significant radiotoxicity, posing a serious health risk upon ingestion or inhalation. The study of plutonium citrate is primarily focused on its behavior in the environment and its effects on living organisms. This research is crucial for understanding the potential risks associated with plutonium contamination, particularly in nuclear accidents or waste disposal scenarios. Additionally, research explores its potential medical applications, though these are limited due to its radiotoxicity. Plutonium citrate's importance lies in its contribution to understanding the complex chemistry of plutonium and its potential impact on human health and the environment.'

plutonium citrate: RN given refers to 2:1 citric:Pu(4+) salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	108004
MeSH ID	M0229056

Synonym
plutonium citrate
ccris 9233
1,2,3-propanetricarboxylic acid, 2-hydroxy-, plutonium(4+) salt (2:1)
(239) plutonium citrate
(239)pu citrate
7261-07-6
2-(carboxymethyl)-2-hydroxybutanedioate;plutonium

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (7.69)	18.7374
1990's	7 (53.85)	18.2507
2000's	5 (38.46)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
citric acid, anhydrous Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.. citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.	3.94	13	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
phytic acid Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.	2.02	1	inositol phosphate
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.38	2	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
spermine [no description available]	1.99	1	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	1.99	1	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	2.42	2	pentacarboxylic acid	copper chelator
plutonium Plutonium: A naturally radioactive element of the actinide metals series. It has the atomic symbol Pu, and atomic number 94. Plutonium is used as a nuclear fuel, to produce radioisotopes for research, in radionuclide batteries for pacemakers, and as the agent of fission in nuclear weapons.	3.94	13	actinoid atom; f-block element atom
plutonium nitrate plutonium nitrate: RN given refers to cpd with MF of Pu-HNO3	2.38	2
plutonium phytate [no description available]	2.02	1
plutonium dioxide plutonium dioxide: RN given refers to cpd with MF of Pu-O2	2.05	1

Condition	Relationship Strength	Studies
Experimental Radiation Injuries [description not available]	2.05	1
Bone Cancer [description not available]	3.09	5
Cancer, Radiation-Induced [description not available]	3.23	6
Osteogenic Sarcoma [description not available]	2.91	4
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.09	5
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.91	4
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.02	1
Leukemia, Radiation-Induced Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.	2.69	3
Leukemia, Lymphocytic [description not available]	1.98	1
Germinoblastoma [description not available]	2.69	3
Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.	1.98	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.69	3
Atypical Lipomatous Tumor [description not available]	1.98	1
Kahler Disease [description not available]	1.98	1
Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)	1.98	1
Liposarcoma A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)	1.98	1
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	1.98	1
Stunted Growth [description not available]	1.95	1
Experimental Mammary Neoplasms [description not available]	1.95	1
Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.	1.95	1
Weight Gain Increase in BODY WEIGHT over existing weight.	1.95	1
Hematologic Malignancies [description not available]	2	1
Cancer of the Thymus [description not available]	2	1
Leukemia, Pre-B-Cell [description not available]	2	1
Thymus Neoplasms Tumors or cancer of the THYMUS GLAND.	2	1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	2	1
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	2	1

plutonium citrate

Description

Cross-References

Synonyms (7)

Research

Studies (13)

Market Indicators

Research Demand Index: 12.54

Study Types